SCHEMBL983752

SCHEMBL983752

CC1CN(CC(=O)c2ccc(F)cc2)CCN1C(=O)c1nn(C)cc1Cl

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 17/20 0.71
HTR2C P28335 10/20 0.71
KCNH2 Q12809 2/20 0.71
ALDH1A1 P00352 2/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CCR1 P32246 1/20 0.41
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL983751 1.00 HTR2A (0.71) HTR2AHTR2CKCNH2ALDH1A1TSHR
SCHEMBL12948616 1.00 HTR2A (0.71) HTR2AHTR2CKCNH2ALDH1A1TSHR
Hydrochloric Acid SCHEMBL981411 0.99 HTR2A (0.70) HTR2AHTR2CKCNH2ALDH1A1TSHR
Hydrochloric Acid SCHEMBL981412 0.99 HTR2A (0.70) HTR2AHTR2CKCNH2ALDH1A1TSHR
Hydrochloric Acid SCHEMBL986103 0.99 HTR2A (0.70) HTR2AHTR2CKCNH2ALDH1A1TSHR
SCHEMBL12922351 0.89 HTR2A (0.57) HTR2AHTR2CKCNH2ALDH1A1TSHR
SCHEMBL12922350 0.89 HTR2A (0.57) HTR2AHTR2CKCNH2ALDH1A1TSHR
SCHEMBL17586530 0.89 HTR2A (0.72) HTR2AHTR2CKCNH2ALDH1A1TSHR
SCHEMBL13671729 0.88 HTR2A (0.71) HTR2AHTR2CKCNH2
SCHEMBL3134483 0.88 HTR2A (0.71) HTR2AHTR2CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434692-B2 Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2016-09-06 US claimed
US-20130217700-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-08-22 US claimed
US-20100004264-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2010-01-07 US claimed
US-20210380537-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2021-12-09 US disclosed
US-20210128528-A1 USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS AXOVANT SCIENCES GMBH (CH) 2021-05-06 US disclosed
US-20200048205-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2020-02-13 US disclosed
US-10351531-B2 Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2019-07-16 US disclosed
WO-2019033068-A1 USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS AXOVANT SCIENCES GMBH (CH) 2019-02-14 WO disclosed
US-20190046506-A1 USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS AXOVANT SCIENCES GMBH (CH) 2019-02-14 US disclosed
US-20170320831-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2017-11-09 US disclosed
US-9732039-B2 Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto Arena Pharmeceuticals, Inc. (US) 2017-08-15 US disclosed
US-9434692-B2 Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2016-09-06 US disclosed
US-20160075660-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2016-03-17 US disclosed
EP-2066641-B1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2014-06-04 EP disclosed
US-20130217700-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-08-22 US disclosed
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2011-01-27 US disclosed
US-20100004264-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2010-01-07 US disclosed
EP-2066641-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2009-06-10 EP disclosed
WO-2008042388-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004264-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR5A, HTR2A, HTR2B HTR2A 2/4885HTR2C 7/4885KCNH2 527/4885
US-20200048205-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR5A, HTR2A, HTR2C HTR2A 2/4885HTR2C 3/4885KCNH2 487/4885
US-20130217700-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR2A, HTR5A, HTR2C HTR2A 1/4885HTR2C 3/4885KCNH2 580/4885
US-20210380537-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR5A, HTR2A, HTR2B HTR2A 2/4885HTR2C 7/4885KCNH2 527/4885
US-20170320831-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR5A, HTR2A, HTR3A HTR2A 2/4885HTR2C 6/4885KCNH2 537/4885
US-10351531-B2 Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto HTR5A, HTR2A, HTR3A HTR2A 2/4885HTR2C 6/4885KCNH2 537/4885
US-20210128528-A1 USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS HTR2A, HTR1A, HTR3B HTR2A 1/4885HTR2C 5/4885KCNH2 796/4885
US-20190046506-A1 USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS HTR2A, HTR1A, HTR3B HTR2A 1/4885HTR2C 5/4885KCNH2 796/4885
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR HTR5A, HTR2A, HTR3A HTR2A 2/4885HTR2C 4/4885KCNH2 1181/4885
US-20160075660-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR5A, HTR2A, HTR2B HTR2A 2/4885HTR2C 7/4885KCNH2 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.